• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

盐酸司维拉姆暴露对血液透析患者颈动脉内膜中层厚度的影响。

Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients.

机构信息

Epidemiology and Research Unit, E. Wolfson Medical Center, Holon, Israel.

出版信息

Nephron Clin Pract. 2011;117(2):c83-8. doi: 10.1159/000319654. Epub 2010 Aug 6.

DOI:10.1159/000319654
PMID:20714166
Abstract

BACKGROUND

Elevated phosphorus (P) and calcium (Ca)-P product (Ca × P) are associated with vascular calcification and cardiovascular disease (CVD) morbidity and CVD and all-cause mortality.

OBJECTIVES

This study examined the effect of sevelamer hydrochloride exposure (regardless of calcium carbonate exposure) on carotid and femoral intima media thickness (IMT), reliable surrogate measures of prospective intimal thickening, in end-stage renal disease patients on maintenance hemodialysis.

METHODS

The present cross-sectional study is nested in the Sevelamer hydrochloride and ultrasound-measured femoral and carotid intima media thickness progression in end-stage renal disease (SUMMER) clinical trial. Carotid and femoral arteries were visualized in B-mode ultrasonography. Log-transformed IMT was compared by sevelamer hydrochloride exposure and modeled using multiple linear regression.

RESULTS

Forty-five subjects were exposed to sevelamer hydrochloride and 130 were not. Exposed subjects had significantly lower carotid IMT, an association which persisted in the multiple linear regression model even after controlling for potentially confounding variables including serum Ca, history of CVD and body weight. Exposed subjects had lower low-density lipoprotein cholesterol levels and significantly higher parathyroid hormone, but no differences in P, Ca and Ca × P.

CONCLUSIONS

Sevelamer hydrochloride was associated with lower carotid IMT. This association may be mediated through reduction in Ca load, low-density lipoprotein cholesterol lowering or some other pleiotropic effect.

摘要

背景

升高的磷 (P) 和钙 (Ca)-P 产物 (Ca × P) 与血管钙化和心血管疾病 (CVD) 发病率以及 CVD 和全因死亡率相关。

目的

本研究检测了盐酸司维拉姆暴露(无论是否暴露碳酸钙)对维持性血液透析的终末期肾病患者颈动脉和股动脉内膜中层厚度(IMT)的影响,IMT 是内膜进行性增厚的可靠替代指标。

方法

本横断面研究嵌套在盐酸司维拉姆和超声测量的终末期肾病患者股动脉和颈动脉内膜中层厚度进展研究(SUMMER)临床试验中。采用 B 型超声对颈动脉和股动脉进行可视化。采用多线性回归模型比较盐酸司维拉姆暴露的对数转换 IMT。

结果

45 例患者暴露于盐酸司维拉姆,130 例患者未暴露于盐酸司维拉姆。暴露组的颈动脉 IMT 明显较低,即使在控制血清 Ca、CVD 病史和体重等潜在混杂变量后,这种关联在多线性回归模型中仍然存在。暴露组的低密度脂蛋白胆固醇水平较低,甲状旁腺激素水平明显较高,但 P、Ca 和 Ca × P 无差异。

结论

盐酸司维拉姆与较低的颈动脉 IMT 相关。这种关联可能通过降低 Ca 负荷、降低低密度脂蛋白胆固醇或其他多效性作用来介导。

相似文献

1
Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients.盐酸司维拉姆暴露对血液透析患者颈动脉内膜中层厚度的影响。
Nephron Clin Pract. 2011;117(2):c83-8. doi: 10.1159/000319654. Epub 2010 Aug 6.
2
C-reactive protein and carotid and femoral intima media thickness: predicting inflammation.C反应蛋白与颈动脉和股动脉内膜中层厚度:预测炎症
Clin Nephrol. 2013 Dec;80(6):449-55. doi: 10.5414/CN108067.
3
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.盐酸司维拉姆与醋酸钙用于腹膜透析患者的疗效和安全性
Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488. Epub 2008 Sep 27.
4
Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.新型磷结合剂比沙洛美对从盐酸司维拉姆转换过来的血液透析患者的临床疗效。
Ther Apher Dial. 2014 Jun;18 Suppl 2:8-12. doi: 10.1111/1744-9987.12228.
5
Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.在血液透析患者中,单独使用或与碳酸钙联合使用时,盐酸司维拉姆与考来替胺的比较。
Ther Apher Dial. 2008 Apr;12(2):126-32. doi: 10.1111/j.1744-9987.2008.00557.x.
6
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.血液透析患者中烟酸和盐酸司维拉姆这两种磷结合剂的疗效比较。
Saudi J Kidney Dis Transpl. 2012 Sep;23(5):934-8. doi: 10.4103/1319-2442.100865.
7
Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.盐酸司维拉姆:用于血液透析的终末期肾病患者高磷血症治疗的综述
Drugs. 2008;68(1):85-104. doi: 10.2165/00003495-200868010-00006.
8
Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients.颈动脉内膜中层厚度可预测血液透析患者的心血管死亡率。
Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S76-9. doi: 10.1053/ajkd.2003.50090.
9
A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.血液透析患者中碳酸司维拉姆与醋酸钙对骨转换生物标志物影响的比较。
Ren Fail. 2006;28(8):701-7. doi: 10.1080/08860220600925388.
10
Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.血液透析患者从盐酸司维拉姆转换为比沙洛姆对实验室指标的影响。
Ther Apher Dial. 2014 Jun;18 Suppl 2:2-7. doi: 10.1111/1744-9987.12227.

引用本文的文献

1
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
2
A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials.一项基于随机试验的慢性肾脏病高磷血症治疗的网络荟萃分析。
Sci Rep. 2025 Jan 15;15(1):2012. doi: 10.1038/s41598-024-84942-8.
3
Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS.
采用曲线下面积评估方法研究长期磷控制对血液透析患者心血管死亡率的影响:来自 DOPPS 的结果。
Nephrol Dial Transplant. 2020 Oct 1;35(10):1794-1801. doi: 10.1093/ndt/gfaa054.
4
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3.
5
Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.碳酸司维拉姆:用于治疗慢性肾脏病成人高磷血症的药物评价。
Drugs. 2014 May;74(7):771-92. doi: 10.1007/s40265-014-0215-7.
6
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.司维拉姆再探讨:对慢性肾脏病和终末期肾病患者内皮及心血管危险因素的多效性作用
Ther Adv Cardiovasc Dis. 2013 Dec;7(6):322-42. doi: 10.1177/1753944713513061.
7
Effects of the Use of Non-Calcium Phosphate Binders in the Control and Outcome of Vascular Calcifications: A Review of Clinical Trials on CKD Patients.使用非磷酸钙结合剂对血管钙化控制及转归的影响:慢性肾脏病患者临床试验综述
Int J Nephrol. 2011;2011:758450. doi: 10.4061/2011/758450. Epub 2011 Jun 9.